First quarter 2024 results
First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
Paul Hudson comments on Q1 2024 results
We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson
Chief Executive Officer